RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets

Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy. On January 20, RBC Capital increased Ascendis Pharma A/S (NASDAQ:ASND)’s price target to $250 from $245 while maintaining an Outperform rating on the company. The firm’s improved projection comes after Ascendis Pharma A/S (NASDAQ:ASND) announced major goals for 2026, with the company estimating maintaining launch momentum for Yorvipath with no drop in patient intakes.

Ascendis Pharma A/S (NASDAQ:ASND) stated that the European potential could be more significant, with 150,000-200,000 patients vs 70,000-90,000 in the US, though the complex payer system demands patience. The company anticipates that the revenue split would eventually come to 60:40 U.S. to non-U.S.

In terms of financial estimates, Ascendis Pharma A/S (NASDAQ:ASND) reiterated its objective of €500 million in operating cash flow for this year and more than €5 billion in top-line revenue by 2030, in contrast to the consensus of around €3.5 billion, with Yorvipath predicted to earn €5-8 billion at its height.

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.

While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.